| Code | CSB-RA025833MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to bevacizumab-awwb, designed to specifically bind and neutralize vascular endothelial growth factor A (VEGFA). VEGFA is a critical signaling protein that promotes angiogenesis, the formation of new blood vessels from existing vasculature. By binding to VEGF receptors on endothelial cells, VEGFA stimulates proliferation, migration, and survival of vascular endothelial cells. Dysregulated VEGFA expression and excessive angiogenesis are hallmarks of various pathological conditions, including solid tumors, age-related macular degeneration, and diabetic retinopathy. In cancer, VEGFA-driven neovascularization supports tumor growth, progression, and metastasis by ensuring adequate nutrient and oxygen supply.
Bevacizumab-awwb is an FDA-approved biosimilar of the original bevacizumab, a humanized IgG1 monoclonal antibody that binds all isoforms of VEGFA. This research-grade biosimilar antibody serves as a valuable tool for investigating VEGFA-mediated angiogenic pathways, studying tumor microenvironment dynamics, evaluating anti-angiogenic therapeutic strategies, and exploring mechanisms of resistance to VEGF inhibition in preclinical models.
There are currently no reviews for this product.